JP Patent

JP2017526693A — スミス‐マゲニス症候群を治療するためのタシメルテオン

Assigned to Vanda Pharmaceuticals Inc · Expires 2017-09-14 · 9y expired

What this patent protects

本発明の実施形態は、スミス‐マゲニス症候群（ＳＭＳ）を有する個人における睡眠障害の治療に関する。

USPTO Abstract

本発明の実施形態は、スミス‐マゲニス症候群（ＳＭＳ）を有する個人における睡眠障害の治療に関する。

Drugs covered by this patent

Patent Metadata

Patent number: JP2017526693A
Jurisdiction: JP
Classification: —
Expires: 2017-09-14
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.